Pyoderma - 18 Studies Found
| Withdrawn |
: Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum : Pyoderma Gangrenosum : 2008-06-02 : Drug: adalimumab 40 mg weekly adalimumab injection. |
| Completed |
: Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease :
: Other: Usual care advanced dressings, off-loading, venous ulcer compression, arterial screening |
| RECRUITING |
: Spesolimab in Pyoderma Gangrenosum : Pyoderma Gangrenosum : 2024-11-21 : 900 mg of spesolimab intravenously (IV) administered at Weeks 0, 3, 6, 9, 12 and 15. |
| RECRUITING |
: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) : Pyoderma Gangrenosum : 2024-11-21 : Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks. |
| NOT_YET_RECRUITING |
: Deucravacitinib in PG : Pyoderma Gangrenosum : 2024-11-21 : 6 mg tablet |
| RECRUITING |
: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum : Pyoderma Gangrenosum : 2024-11-21 : vilobelimab infusion |